The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial
- Conditions
- Squamous Cell CarcinomaAdenocarcinomaCarcinoma, AdenosquamousUterine Cervical Neoplasms
- Interventions
- Registration Number
- NCT02394652
- Lead Sponsor
- University Health Network, Toronto
- Brief Summary
Cervical cancer remains an important health problem worldwide. Poor tumor oxygenation (hypoxia) is associated with inferior survival in cervical cancer and resistance to radiation treatment. Hypoxia-modifying therapies improve survival, but existing therapies are impractical and/or toxic. Metformin, a non-toxic drug for diabetes, has been shown to decrease tumor hypoxia in animal studies and its use is associated with better survival in diabetic cancer patients. It is hypothesized that metformin may decrease cervical tumor hypoxia and thereby improve tumor response to radiation and survival in patients with locally advanced cervix cancer.
This is a randomized, multicenter phase II study of standard chemoradiation in combination with metformin versus standard chemoradiation alone in women with locally advanced cervix cancer. Women randomized to the metformin group will take metformin starting 1 week prior to standard chemoradiation and throughout the duration of external radiation treatment. Tumor hypoxia will be measured by a special X-ray test called positron emission test (PET) performed with a hypoxia dye called FAZA. The main purpose of this study is to see if metformin decreases tumor hypoxia measured on FAZA-PET; information about response and side effects will also be collected.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 16
- Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IB2-IVA
- Planned for radical radiotherapy and concurrent cisplatin chemotherapy.
- Able to receive weekly cisplatin.
- No prior anticancer treatment for cervical cancer
- ECOG 0 or 1
- Life expectancy of greater than 3 months.
- Normal organ and marrow function
- Able to take oral medications.
- Ability to understand and willing to sign the consent form
- Willing to undergo biopsies of cervical tumor.
- Evidence of distant metastases
- Receiving any other investigational agents concurrently or within 4 weeks.
- Known diabetes mellitus.
- Currently taking metformin, sulfonylureas, thiazolidinediones or insulin.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or cisplatin.
- Any condition associated with increased risk of metformin-associated lactic acidosis
- Uncontrolled inter-current illness
- Pregnant women
- History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for >=5 years.
- Known HIV-positive
- History of bowel obstruction or malabsorption syndromes
- History of active clinically significant bleeding
- Contraindications to radiotherapy
- Taking drug disulfiram (antabuse).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Experimental: Metformin with Standard Chemoradiation FAZA Metformin: About 1 week prior to the start of chemoradiation, take 850 mg of metformin, orally, once a day for 3 days, followed by 850 mg twice a day and continued for the duration of external radiation. Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation. FAZA-PET scan at baseline and after about 1 week of metformin (just prior to the start of chemoradiation) Standard Chemoradiation FAZA Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation. FAZA-PET scan at baseline and about 1 week later (just prior to the start of chemoradiation). Experimental: Metformin with Standard Chemoradiation Metformin Metformin: About 1 week prior to the start of chemoradiation, take 850 mg of metformin, orally, once a day for 3 days, followed by 850 mg twice a day and continued for the duration of external radiation. Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation. FAZA-PET scan at baseline and after about 1 week of metformin (just prior to the start of chemoradiation) Experimental: Metformin with Standard Chemoradiation Cisplatin Metformin: About 1 week prior to the start of chemoradiation, take 850 mg of metformin, orally, once a day for 3 days, followed by 850 mg twice a day and continued for the duration of external radiation. Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation. FAZA-PET scan at baseline and after about 1 week of metformin (just prior to the start of chemoradiation) Standard Chemoradiation Cisplatin Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation. FAZA-PET scan at baseline and about 1 week later (just prior to the start of chemoradiation).
- Primary Outcome Measures
Name Time Method • Change in fractional hypoxic volume of the tumor on FAZA-PET scan before and after 1 week of metformin. About 7 days
- Secondary Outcome Measures
Name Time Method Disease-free survival 2 years Biomarkers of response to metformin. 2 years Acute and late gastrointestinal and genitourinary toxicities following metformin and chemoradiation. 2 years Effect of metformin on endogenous hypoxia and other markers. About 7 days
Trial Locations
- Locations (5)
Tom Baker Cancer Centre
🇨🇦Calgary, Alberta, Canada
Centre Hospitalier De L'Université de Montréal
🇨🇦Montréal, Quebec, Canada
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
Princess Margaret Cancer Centre
🇨🇦Toronto, Ontario, Canada
Hôpital Maisonneuve-Rosemont
🇨🇦Montréal, Quebec, Canada